<SEC-DOCUMENT>0001193125-17-105066.txt : 20170331
<SEC-HEADER>0001193125-17-105066.hdr.sgml : 20170331
<ACCEPTANCE-DATETIME>20170331070833
ACCESSION NUMBER:		0001193125-17-105066
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170331
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170331
DATE AS OF CHANGE:		20170331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		17727955

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d379388d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;31, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2017, FibroGen, Inc. issued a press release in which it
reported approval by the China Food and Drug Administration of its clinical trial application in China for a Phase 2/3 pivotal trial of roxadustat in anemia associated with lower risk myelodysplastic syndromes. The Company received notification of
the approval on March&nbsp;21, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of such press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated
herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated with Lower Risk MDS&#148; dated March&nbsp;31, 2017</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FIBROGEN, INC.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Legal Counsel</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated with Lower Risk MDS&#148; dated March&nbsp;31, 2017</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d379388dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g379388g0331081219532.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>NEWS RELEASE</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:4pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIBROGEN ANNOUNCES CHINA FDA APPROVAL OF CTA TO CONDUCT PIVOTAL PHASE 2/3 CLINICAL TRIAL OF ROXADUSTAT IN
ANEMIA ASSOCIATED WITH LOWER RISK MDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expands Roxadustat Development Program Into Oncology-Related Anemia in China </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, March&nbsp;31, 2017 &#151; FibroGen, Inc. (NASDAQ: FGEN), a science-based biopharmaceutical company, today announced the approval by the China
Food and Drug Administration (CFDA) of the Company&#146;s clinical trial application (CTA) in China for a Phase 2/3 pivotal trial of roxadustat in anemia associated with lower risk myelodysplastic syndromes (MDS). FibroGen and AstraZeneca (NYSE:AZN)
are collaborating on the development and commercialization of roxadustat in China, the U.S., and other major markets. FibroGen is conducting all clinical trials and regulatory submissions in both the U.S. and China, and will retain all regulatory
licenses and manufacturing permits in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Phase 2/3 clinical trial will evaluate the safety and efficacy of roxadustat in <FONT
STYLE="white-space:nowrap">non-transfusion</FONT> dependent, lower risk MDS patients with anemia. The initial open-label portion of the study is expected to enroll up to 40 patients, with 135 patients planned for the randomized, double-blind,
placebo-controlled Phase 3 portion of the study, in which subjects will be randomized 2:1 to receive roxadustat or placebo three-times-weekly (TIW) for 26 weeks. The Company expects to initiate this Phase 2/3 study in the second half of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company anticipates initiating a U.S. Phase 3 MDS clinical trial in the third quarter of 2017. The pivotal U.S. study is a randomized,
double-blind, placebo-controlled study designed to evaluate the efficacy and safety of roxadustat for the treatment of anemia in transfusion-dependent lower risk MDS patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MDS Anemia in China </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Myelodysplastic syndromes
(&#147;MDS&#148;) are a group of disorders characterized by poorly formed or dysfunctional blood cells, leading to anemia in most patients. Anemia is associated with increased risk of hospitalization, cardiovascular complication, need for blood
transfusion, exacerbation of other serious medical conditions, and death. In addition, anemia frequently leads to significant fatigue, cognitive dysfunction, and decreased quality of life. Currently, there is no medicine approved for treating anemia
in MDS in China. MDS patients typically rely on repeated blood transfusions; however, in China, due to limited blood supply and challenges in accessing transfusions, anemia in most MDS patients is undertreated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat <FONT
STYLE="white-space:nowrap">(FG-4592)</FONT> is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> orally administered small molecule in global Phase 3 clinical development as a potential therapy for
anemia associated with chronic kidney disease (CKD). Roxadustat </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is a hypoxia-inducible factor prolyl hydroxylase inhibitor <FONT STYLE="white-space:nowrap">(HIF-PHI)</FONT> that promotes erythropoiesis through increasing endogenous erythropoietin, improving
iron regulation, and reducing hepcidin. Administration of roxadustat has been shown in clinical trials to induce coordinated erythropoiesis &#150; increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal
physiologic range in multiple subpopulations of CKD patients &#150; including in the presence of inflammation and without a need for supplemental intravenous iron.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat is currently advancing through Phase 3 clinical trials worldwide, supported by extensive Phase 2 clinical data demonstrating correction and
maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. To date, roxadustat has been evaluated in Phase 1 and Phase 2 studies, involving more than 1,400 subjects. Globally, a total of 15 Phase 3 studies, with target
enrollment of about 10,000 patients worldwide, are currently being conducted to support independent regulatory approvals of roxadustat in both <FONT STYLE="white-space:nowrap">non-dialysis-dependent</FONT> and dialysis-dependent CKD patients in the
U.S., Europe, Japan, and China. Roxadustat is also entering a Phase 3 clinical trial in the U.S., and a Phase 2/3 in China for treatment of anemia in patients with myelodysplastic syndromes (MDS). For information about roxadustat studies currently
recruiting patients, please visit <U>www.clinicaltrials.gov</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company
discovering and developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF)
biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat <FONT STYLE="white-space:nowrap">(FG-4592),</FONT> the company&#146;s most advanced product candidate, is an oral
small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS).
Pamrevlumab <FONT STYLE="white-space:nowrap">(FG-3019),</FONT> a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase&nbsp;2 clinical development for the treatment of idiopathic pulmonary
fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the
Company&#146;s product candidate, roxadustat, in China, the potential safety and efficacy profile of roxadustat, including in anemia associated with myelodysplastic syndromes, the potential for regulatory submissions, and our clinical plans,
including timing for planned initiation of clinical trials in China and the U.S. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and
timing of our various <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical programs, including enrollment and conduct of our clinical trials, and our collaboration partners&#146; clinical trials for roxadustat in anemia associated with
CKD, the continued progress of our plans and programs in China, including clinical development of and regulatory filing outcomes for anemia associated with myelodysplastic syndromes, and other matters that are described in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (415) <FONT
STYLE="white-space:nowrap">978-1433</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kbergman@fibrogen.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g379388g0331081219532.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g379388g0331081219532.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I -X# 2(  A$! Q$!_\0
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F/#.@?8+F6.23SFDW)TP<?X5TE%5+$U)4U2;T1,</3C4=5+5G_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
